Skip to main content
. 2016 Feb 11;11(2):e0148316. doi: 10.1371/journal.pone.0148316

Table 1. GLA gene variants and results of biochemical testing in a population of SFN patients (n = 725).

Patient c.position variant p.position variant Class α-Gal A (mmol/L) Lyso-GB3 (nmol/mmol creatinine)
1 F c.-40G>C - 2 57.4 NA
2 F c.-8C>G - 2 68.8 NA
3 F c.48T>G p.Leu16Leu 2 96.7 NA
4 F c.123C>T p.Thr41Thr 2 72.9 NA
5 F c.352C>T p.Arg118Cys 4 59.2 0
6 F c.376A>G p.Ser126Gly 2 52.6 0
7 F c.801+21T>C - 2 43.2 0
8 F c.937G>T p.Asp313Tyr 3 62.4 NA
9 F c.937G>T p.Asp313Tyr 3 60.6 NA
10 M c.937G>T p.Asp313Tyr 3 30.3 0
11 F c.937G>T p.Asp313Tyr 3 51.5 0
12 F c.937G>T p.Asp313Tyr 3 63.5 0
13 F c.999+11_12ins11+999+16_20del5 - 2 78.9 NA

α-Gal A: α-galactosidase A enzyme activity, F: female, Lyso-GB3: lysosomal globotriaosylceramide, M: male, NA: not available.